首页> 美国卫生研究院文献>Clinical and Experimental Gastroenterology >A study of the circulating fibroblast growth factor 21 as a novel noninvasive biomarker of hepatic injury in genotype-4 chronic hepatitis C: Egyptian patients and their response to direct-acting antiviral agents
【2h】

A study of the circulating fibroblast growth factor 21 as a novel noninvasive biomarker of hepatic injury in genotype-4 chronic hepatitis C: Egyptian patients and their response to direct-acting antiviral agents

机译:循环成纤维细胞生长因子21作为4型慢性丙型肝炎肝损伤的新型非侵入性生物标志物的研究:埃及患者及其对直接作用抗病毒药的反应

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundFibroblast growth factor (FGF) 21 was reported to be induced by different injurious agents, including chronic hepatitis C (CHC) virus, affecting the liver. The aims of this study were to evaluate the FGF21 levels in CHC patients before and after the treatment with direct-acting antiviral agents (DAAs) in comparison to that in control subjects and to correlate these levels with insulin resistance (IR), lipid profile, and fibrosis stages.
机译:背景技术据报道,成纤维细胞生长因子(FGF)21由包括肝脏的慢性丙型肝炎(CHC)病毒在内的各种伤害性因子引起。这项研究的目的是评估与直接对照药物相比,直接作用抗病毒药物(DAA)治疗前后的CHC患者的FGF21水平,并将这些水平与胰岛素抵抗(IR),脂质分布,和纤维化阶段。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号